Mechanisms of poststroke fatigue by De Doncker, W et al.
 1 
 
Mechanisms of post-stroke fatigue  
William De Doncker1, Robert Dantzer2, Heidi Ormstad3, Annapoorna Kuppuswamy1 
1 Institute of Neurology, UCL, UK 
2 Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, 
Texas 





















Dr Annapoorna Kuppuswamy 
Institute of Neurology,  
Box 146, 33 Queen Square 







Introduction  1 
 2 
Stroke is a leading cause of disability [1], with increasing incidence [2] and higher survival rates [3], set 3 
to make management of long term consequences of stroke, one of the biggest challenges of the 4 
future. Of the many sequelae of stroke, the least understood, most difficult to manage and that which 5 
has significant impact on daily life are chronic affective symptoms such as fatigue, pain and mood 6 
disturbances [4–6]. There is an urgent need to understand the underlying biological mechanisms of 7 
chronic affective symptoms to develop evidence based management strategies and possibly even 8 
treatments. In this review we focus on post-stroke fatigue, a common debilitating symptom that has 9 
significant implications for morbidity, disability, quality of life and mortality [4–6]. Management of 10 
fatigue has been identified by stroke survivors as their top unmet need [7–9] and is a top priority for 11 
further research [10]. Fatigue affects a significant percentage of stroke survivors, ranging from 25% to 12 
85%, the large variability a result of the definition and the scale used to measure  fatigue, [11–13] 13 
including those with mild strokes and little disability [14]. Here, we review recent developments in our 14 
understanding of potential triggers for fatigue after stroke, mechanisms that might perpetuate and 15 
maintain fatigue in the long term and theoretical models of post-stroke fatigue that might usefully 16 
inform future research into post-stroke fatigue.  17 
 18 
How do we define and measure fatigue? 19 
 20 
Fatigue is a term that is instantly recognisable and understood by all, however, defining fatigue for 21 
purposes of quantification and comparison across individuals is notoriously difficult. The difficulty is 22 
partly a result of inability to distinguish between the phenomenon of fatigue and its impact. Despite 23 
difficulty in defining fatigue, one of the key differences between physiological and pathological fatigue 24 
is its resistance to rest and the report of post-stroke fatigue being a distinctly different experience 25 
from pre-stroke ‘normal’ fatigue [15]. Beyond these distinctions, there is little consensus on a 26 
definition for post-stroke fatigue. Several attempts have been made to capture the felt experience of 27 
fatigue [16–18]. “Fatigue is a multidimensional motor-perceptive, emotional and cognitive 28 
experience” [16]; “Fatigue is a feeling of lack of energy, weariness, and aversion to effort” [17]; 29 
“decrease or loss of abilities associated with a heightened sensation of physical or mental strain, even 30 
without conspicuous effort, an overwhelming feeling of exhaustion, which leads to inability or 31 
difficulty to sustain even routine activities and which is commonly expressed verbally as a loss of drive” 32 
[18]. Whilst definitions based on felt experience define fatigue from a stroke survivors’ perspective, 33 
others have attempted to define fatigue from a mechanistic perspective [19,20]. “Pathological fatigue 34 
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is, thus, best understood as an amplified sense of normal (physiological) fatigue that can be induced  1 
by changes in one or more variables regulating work output. Fatigue could develop during a disease 2 
because of dissociation between the level of internal input (motivational and limbic) and that of 3 
perceived exertion from applied effort” [19]. “A plausible mechanism of post-stroke fatigue wherein 4 
inflammation, the commonest cause of fatigue in neurological conditions, sets in motion a series of 5 
changes that include alterations in sensorimotor processing such as sensory prediction associated with 6 
effort mechanisms leading to chronic fatigue in stroke survivors” [20].  Little has been done to 7 
understand the neurobiological basis of chronic post-stroke fatigue beyond attempting to define it 8 
mechanistically, and the only validated tools available to measure fatigue are in the form of 9 
questionnaires. The most commonly used scale is the Fatigue Severity Scale [4,5,11,13,21–25] with 10 
Neurological Fatigue Index [26], Fatigue Assessment Scale [27,28] and Multidimensional Fatigue 11 
Inventory [29–32] also used in several studies. These questionnaires capture both the multi-12 
dimensional nature of fatigue and its impact on daily life. The information captured by the 13 
questionnaires and the above definitions allow us to develop plausible mechanistic hypothesis for 14 
chronic post-stroke fatigue. The repeated references to ‘effort’ in the definitions, and effort related 15 
statements in the questionnaires, suggest that post-stroke fatigue may be a disorder of effort. We 16 
elaborate on evidence that might support this hypothesis in later sections of this review.  17 
 18 
Incidence, overlap and impact of post-stroke fatigue  19 
 20 
Fatigue after stroke is highly debilitating, with a significant impact on return to work and a major effect 21 
on economy [33]. Several studies have documented the rates at which fatigue is reported in stroke 22 
survivor populations, which ranges from 25% to 85% [13]. There could be several contributing factors 23 
for the reported differences in incidence. Use of different fatigue scales that measure different aspects 24 
of fatigue, combined with a lack of consensus on a ‘cut-off’ point that differentiates the low from high 25 
fatigue are limiting factors. Nevertheless, examining the incidence and overlap of fatigue with other 26 
affective symptoms could potentially inform our knowledge about origins of fatigue and possibly even 27 
the mechanisms of long-term fatigue. Reports of fatigue six months post-stroke ranges from 40-70% 28 
[4,12,23,34–36] of which anywhere between 29-87% suffer from post stroke depression 29 
[4,9,11,25,37]. A further 33-62% also report sleep problems [4,12] whilst 50-60% suffer from 30 
symptoms of pain [4,38]. Post-stroke anxiety was also correlated with fatigue, but after controlling for 31 
depression, the association was non-significant [39]. The picture is one of a complex incidence with 32 
significant overlap with other affective symptoms. This has previously led to mistaken belief that post-33 
stroke fatigue may be secondary to other primary disorders, however, recent work has highlighted 34 
 4 
 
the primary occurrence of fatigue after stroke [40], for example, almost everyone with depression 1 
report fatigue, but not all with fatigue have depression [41]. This complex picture of incidence is 2 
perhaps suggestive of common origins or partial overlap of pathways that mediate affective 3 
disturbances alongside independent mediators of fatigue.  4 
 5 
Investigations have also studied the influence of characteristics such as the type of stroke, age and 6 
gender on incidence of fatigue, which might provide some clues for origins of fatigue. There is no 7 
reported difference in incidence of fatigue between hemorrhagic and ischaemic stroke [12]. Some 8 
studies show a positive correlation between degree of fatigue and age, others show no correlation 9 
whilst some others report a higher incidence in  younger stroke survivors [6,12,13,24,42–45]. The lack 10 
of a consistent report of age positively correlating with fatigue is suggestive of post-stroke fatigue 11 
being a direct result of stroke as opposed to a general decline in energy levels with advancing age. A 12 
pragmatic approach to age and fatigue is that younger stroke survivors have higher expectations of 13 
returning to work which may result in higher reports of fatigue [46,47]. Several investigations report 14 
higher incidence of fatigue in female stroke survivors [6,12,24,25,30,45,48], however, this association 15 
has not been consistently reported in the stroke population  [9,11,41,49]. It is unclear why there might 16 
be a difference in fatigue prevalence between the two genders. Interpretation of the difference is 17 
further complicated by higher prevalence of fatigue in females in the general population [50].  18 
  19 
Time line  20 
 21 
Further insight into potential mechanisms can be gained by examining the time course of fatigue after 22 
stroke. As previously mentioned, cross-study comparison is limited by differences in inclusion criteria, 23 
methods of assessing fatigue and assessment at different time points after the stroke. Longitudinal 24 
studies report a consistency in fatigue levels over time [4,13,30,34,50] with some studies reporting an 25 
increase in fatigue prevalence with time [12,35] and others reporting a decrease in fatigue prevalence 26 
from acute stages (1-3 months post-stroke) to 3 months and thereafter remaining stable [30,34]. Post-27 
stroke fatigue can therefore be divided into early and late fatigue, with most studies defining early as 28 
up to 2-3 months post stroke (acute stage) and late as being anything over 3 months post-stroke 29 
[40,51]. Some stroke survivors suffering from early fatigue continue to suffer high levels of fatigue in 30 
the chronic phase while some stroke survivors only report fatigue in the late phase [40,52,53]. 31 
However, a common pattern amongst the majority of stroke survivors is that early fatigue is a strong 32 
predictor of late fatigue [52]. A differentiation between early and late fatigue might be indicative of 33 
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more than a single trigger and possibly several mediating factors that persist beyond the acute stage 1 
of recovery following a stroke.  2 
 3 
Mechanisms of post-stroke fatigue 4 
  5 
The reported experience of a distinctly different type of fatigue post-stroke, and the development of 6 
fatigue in later stages in some, but not other stroke survivors indicates that post-stroke fatigue may 7 
not be a non-specific reaction to an insult to the brain but a direct result of the stroke. Here, it is worth 8 
reiterating that the majority of stroke survivors report fatigue in the first few weeks after stroke, which 9 
is thought to be a general non-specific reaction to a major disruptive event, hospitalisation and re-10 
adjustment to life after stroke. However, the more debilitating symptom is fatigue that fails to resolve 11 
(or manifests) several weeks after stroke which is thought to be a stroke related sequel. To identify 12 
potential stroke resultant factors that might lead to fatigue, one needs to consider both the direct 13 
tissue damage and biochemical imbalances caused by stroke.  14 
 15 
Lesion location 16 
 17 
The relationship between lesion location and post-stroke fatigue (PSF) remains controversial  18 
[9,18,48,51–53,53–55]. The consensus is that lesion location is not determinant of development of 19 
fatigue [9,11,30,41,49,56], however some studies suggest there may be a higher incidence of fatigue 20 
in sub-cortical strokes when compared to cortical strokes [18]. Sub-cortical strokes may be further 21 
broadly classified as basal ganglia and cerebellar strokes, with basal ganglia strokes more likely to give 22 
rise to fatigue possibly due to disturbances in the limbic-motor integration networks [48,57]. There 23 
isn’t enough information available about detailed distribution of cortical lesions and the incidence of 24 
fatigue, however, any lesion to attention networks could result in fatigue, as poor attention may be a 25 
key element of high effort, a feature of fatigue, as described later in the review [58]. Posterior cerebral 26 
artery strokes resulting in thalamic and brainstem lesions have previously been  associated with high 27 
levels of fatigue. High fatigue in posterior artery strokes may be a result of poor attention mediated 28 
by lesions in attentional networks including the ascending reticular activating system, the lenticular, 29 
hypothalamic and thalamic nuclei [18,50]. Some authors investigated the difference in incidence of 30 
fatigue based on type of lesion. Patients with large vessel stroke experienced greater fatigue than 31 
small vessel involvement [59], whilst other studies report an association with cerebral microbleeds 32 
[60]. Those with stroke reported greater fatigue than transient ischaemic attack (TIA) despite minimal 33 
impairment [14]. An association was seen between fatigue and white matter lesion [61]. These 34 
 6 
 
findings suggest that the presence of a brain lesion rather than post-stroke disability or vascular risk 1 
factors might be important in the aetiology of PSF.  Furthermore, small vessel disease and 2 
development of PSF remains controversial.  Whether lesion location significantly influences the 3 
development of PSF is still an open question and future studies will benefit from a systematic 4 
anatomical correlation of lesion location with fatigue incidence and severity.   5 
 6 
Pro-inflammatory response in the acute phase and subsequent fatigue  7 
 8 
In a systematic review published in 2012 and based on examination of the literature until the last 9 
trimester of 2010, Kutlubaev and colleagues [51] conclude that biological factors probably play a major 10 
role in post stroke fatigue. The mechanisms remain uncertain when looking at possible involvement 11 
of stroke-induced alterations in Hypothalamic-pitutary-adrenal (HPA) axis and in neurotransmitter 12 
systems. In a more recent systematic review, Ponchel et al [62] propose that inflammatory factors 13 
appear to play a role although it still needs to be confirmed. Inflammation is well known to be 14 
associated with fatigue. Several mechanisms have been proposed for this association (64). 15 
Inflammation is mediated by the production and release of proinflammatory cytokines that take place 16 
in the brain during stroke because of the peripheral blood mononuclear cells and is amplified by 17 
resident macrophages, known as microglia [63]. In addition, inflammation can propagate from the 18 
brain to the periphery and vice versa by various communication mechanisms [64]Brain 19 
proinflammatory cytokines can act on neurotransmitters such as serotonin and dopamine by several 20 
mechanisms including alterations in synthesis, packaging in microvesicles, release, and re-uptake. 21 
These mechanisms have been mainly studied in the context of inflammation-induced depression [65]. 22 
Inflammation can also induce oxidative stress which, if anti-inflammatory and antioxidant processes 23 
are deficient, can lead to neurodegeneration that affects primarily dopaminergic neurons in the meso-24 
striatal and mesolimbic pathways [66]. Inflammation can also activate the kynurenine pathway that, 25 
in the context of activated microglia and ongoing neuroinflammation, favors the formation of 26 
neurotoxic kynurenine metabolites to the detriment of neuroprotective kynurenine metabolites, and 27 
therefore enhances further the risk for neurodegeneration. In this section we will examine the 28 
evidence supporting the involvement of each of these mechanisms in stroke-associated fatigue. 29 
Inflammation and fatigue 30 
 31 
There is cumulative evidence for an inflammatory reaction in acute ischemic stroke (AIS), indicating 32 
important interactions between the nervous and immune systems [67,68] . Cytokines are upregulated 33 
in the brain after stroke, and are expressed not only in invading immune cells, but also in glial cells 34 
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and neurons [69]. Brain inflammation caused by the stroke episode does not remain local. As 1 
mentioned in the previous paragraph it propagates to the periphery. Peripheral inflammation 2 
preceding and following a stroke episode has potent modulatory effects on the pathology of stroke. 3 
As inflammation measured by peripheral concentrations of CRP and cytokines in serum plasma 4 
depends on both pre-existing inflammatory clinical status related to e.g., atherosclerosis and 5 
cardiovascular disease and propagation of brain inflammation to the periphery, the results of clinical 6 
studies on the relationship between the inflammatory response following AIS and infarct volume [70–7 
78] and stroke subtype [73] are likely to be very variable. The role of the cytokines involved thus 8 
remain unclear, and whether post ischemic inflammatory responses are deleterious or beneficial to 9 
brain recovery is still a matter of discussion [79,80]. A study, in which the serum levels of 13 cytokines 10 
were evaluated in blood samples taken from 45 acute stroke patients (within 72 h of stroke onset) 11 
and 40 healthy controls [81], showed for instance significantly higher levels of IL-1ra, IL-6, IL-8, IL-9, 12 
IL-10, IL-12, IL-18, and CXCL-1, in stroke patients. The authors concluded that this evidence suggested 13 
an early pro-inflammatory response and an early activation of endogenous immunosuppressive 14 
mechanism following stroke. 15 
Considering fatigue as a dependent variable in the relationship between stroke and inflammation still 16 
adds to the complexity. Despite these difficulties, Ormstad and colleagues investigated the association 17 
between PSF, post stroke depression (PSD), stroke type, infarct volume, laterality, and the levels of 18 
various cytokines [82,83]. PSF and PSD were measured using the Fatigue Severity Scale (FSS) and Beck 19 
Depression Inventory, respectively, at 6, 12, and 18 months after stroke onset. The results indicated a 20 
role for the post stroke pro-inflammatory response in the appearance of PSF. The finding that IL-1 21 
seems to be a predictor of PSF [82] suggests fatigue after stroke could be part of what has been 22 
described as inflammation-induced sickness behavior [84]. Animal models of stroke support this 23 
possibility. For instance, Kunze et. al., [85] showed that experimental stroke in Lewis rats resulted in 24 
behavior consistent with depression whilst Wistar and Sprague-Dawley rats exhibited sickness-like 25 
behavior including fatigue-like behavior. The role of genetic factors has also been taken into 26 
consideration in clinical studies. For instance, Becker and colleagues [86] showed that single 27 
neucleotide polymorphisms in the gene coding for the interleukin-1 receptor antagonist and the gene 28 
coding for TLR4 were associated with high and low fatigue respectively. However, the small size of the 29 
sample (n=39) precludes any definitive conclusion.  30 
A possible neurochemical mechanism for cytokine-mediated fatigue, as discussed earlier could be due 31 
to reduced capability for 5-HT synthesis. However, the ineffectiveness of serotonin reuptake inhibitors 32 
on post-stroke fatigue [87] may rule out serotonergic pathways as a source of fatigue. 33 
Hypodopaminergic activity induced by inflammatory cytokines could potentially be the source of 34 
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cytokine induced fatigue [88,89]. An association between serum cytokines and PSD was not found, 1 
despite numerous reports of an association between PSD and PSF [83]. Recent hypotheses suggest 2 
that glutamate might be the source of affective symptoms related to depression [90,91] but may not 3 
mediate fatigue unrelated to depression.   4 
 5 
Inflammation-mediated activation of the kynurenine pathway and fatigue 6 
Inflammation can induce neurotoxicity by up-regulating the indoleamine 2,3-dioxygenase (IDO) 7 
enzyme (which catalyzes the rate-limiting step in the synthesis of kynurenine (KYN) from tryptophan 8 
(TRP)) in multiple central and peripheral cell types [92,93]. Activation of IDO can be measured  by 9 
increased plasma/serum kynurenine over tryptophan ratio. Kynurenine by itself acts as a ligand of the 10 
aryl hydrocarbon receptor, which generates regulatory T cells. The evidence in favour of such a 11 
mechanism in PSF is still weak. One study in particular reported reduced percentage of circulating 12 
regulatory T cells combined with increased systemic Th17 and pro-inflammatory cytokines and 13 
reduced anti-inflammatory cytokines [94]. In addition, interferon–gamma, the cytokine primarily 14 
responsible for up-regulating IDO was not higher in stroke [81] when compared to healthy controls. 15 
Kynurenine produced in the brain in response to injury or transported from the periphery is further 16 
metabolized into the neuroprotective kynurenine metabolite kynurenic acid (KA) by kynurenine 17 
aminotransferase, and the neurotoxic kynurenine metabolites 3-hydroxykynurenine (3-OH-KYN), and 18 
quinolinic acid (QA) by kynurenine monooxygenase. Activation of microglia, the main cellular source 19 
of proinflammatory cytokines in the brain during neuroinflammation, favors the neurotoxic pathway 20 
at the same time as it results in the extracellular release of glutamate. Whether microglial activation 21 
and the formation of neurotoxic kynurenine metabolites is involved in PSF is not clear. A few studies 22 
based on variations in plasma levels of KYN metabolites indicate activation of the kynurenine pathway 23 
could play a role in post-stroke sequelae [95–98]. Darlington et al. showed increased TRP catabolism 24 
after stroke, and suggest that oxidative tryptophan metabolism contributes to oxidative stress and 25 
brain damage [96]. Brouns et al. showed a correlation between KYN/TRP ratio and stroke severity and 26 
long-term stroke outcome which did not correlate with KA/3-hydroxyanthranillic acid ratio [95]. Mo 27 
et al. showed an up-regulation of IDO activation in ischemic stroke [98]. Ormstad et al., indicated an 28 
increase in TRP oxidation and reduced capability for 5-hydroxytryptamine (5-HT) synthesis in the brain 29 
following AIS [97].  30 
Ormstad et al., also investigated the mechanisms involved in PSD and PSF by studying the relationship 31 
between KYN-pathway activity in the acute ischemic phase and subsequent PSF and PSD in the stroke 32 
sample referred in their previous publication [99]. Compared to the other neutral amino acids that 33 
compete with tryptophan for entry into the brain, plasma levels of TRP index were significantly lower 34 
 9 
 
in patients with an FSS score of ≥4 than in those with an FSS score of <4 at 12 months. However, in 1 
contradiction with the neurotoxic hypothesis the serum levels of KA were significantly higher in 2 
patients with an FSS of score ≥4 than in those with an FSS score of <4 at 18 months. This indicates 3 
stroke patients with PSF might have a lower bioavailability of TRP in the acute stroke phase. In contrast 4 
to PSF, no predictors of PSD were found. These findings suggest that the immune response and IDO 5 
activation that follows AIS can predict PSF but not PSD. Interestingly, the TRP index did not correlate 6 
with fatigue at earlier time points (6 months) and similarly, another study [100] also showed no 7 
correlation between KYN/TRP ratio and fatigue in the very early stages post stroke (1 month). 8 
Emerging evidence appears to suggest that early activation of the KYN pathway does not manifest 9 
immediately as fatigue and depression, but may have long-term consequences which has led to the 10 
proposal of a biopsychosocial model for post-stroke fatigue and depression [101].  11 
 12 
Neurophysiological and behavioural perturbations in chronic post-stroke fatigue  13 
 14 
A particularly challenging aspect of investigating persistent fatigue is the difficulty in differentiating 15 
the causes, from the effects of fatigue. Persistent symptoms such as fatigue result in significant 16 
behavioural and neurophysiological changes, which in turn may cause further fatigue resulting in a 17 
vicious cycle [101]. Thus, identifying the mechanism that first establishes persistent fatigue is not 18 
straightforward. To date, investigations addressing behavioural and neurophysiological underpinnings 19 
of post-stroke fatigue have all been correlational studies, which, for reasons stated below, do provide 20 
minimal insights into the direction of causality between behaviour, fatigue and physiology. However, 21 
causality remains to be confirmed by interventional studies aimed at alleviating fatigue.   22 
 23 
Physical deconditioning is a common sequela after stroke and is believed to trigger PSF. Physical 24 
deconditioning results in fatigue and subsequently, avoidance of physical activity. This further 25 
deteriorates deconditioning and can lead to more fatigue [102]. A recent systematic review however 26 
failed to find an association between fatigue and any measures of physical activity or fitness [103]. 27 
Both motor and cognitive deficits are seen in post-stroke fatigue. In the first year after stroke, in the 28 
absence of any obvious motor deficit, PSF was associated with poor attention and executive function 29 
as measured using phasic attention test and modified stroop task [104]. Whilst fatigue correlated with 30 
attentional and executive function, neither correlated with lesion location. Another independent 31 
investigation [105] confirmed poor executive and memory functions in high PSF in the first 6 months 32 
after stroke. They also showed that side and size of lesion did not correlate with presence of PSF. 33 
Despite subtle differences between the two investigations in terms of PSF definition and tests used to 34 
 10 
 
measure cognitive function, both investigations suggest that at 6 months post-stroke, cognitive 1 
impairment correlates with fatigue with no obvious link to the lesion itself.  2 
 3 
Several studies show that PSF is not correlated with motor deficits. However, a closer look at these 4 
investigations show that tests used to identify motor deficits are normally questionnaire based scores 5 
of activities of daily living such as Barthel index, Rankin scale and National Institutes of Health Stroke 6 
Scale (NIHSS) [25,28,34,46,56,86,104,105].  Some studies use laboratory based tasks to measure 7 
motor function such as action research arm test (ARAT), nine-hole peg test (NHPT), grip strength [106] 8 
and scales such as Fugl-Meyer [107]. These measures, although useful to identify gross motor 9 
limitations relevant to daily life, are not accurate measures of motor impairment. A recent 10 
investigation showed in evenly matched, minimal motor functional deficit high and low PSF groups, 11 
there was a significant reduction in ballistic movement speeds in the affected limb of the high fatigue 12 
group [108] whilst no difference in simple reaction times, attention and information processing speed 13 
was observed. The significantly slower ballistic speeds did not reflect on laboratory test scores, such 14 
as the NHPT times, possibly because tasks such as NHPT capture not only movement velocity but other 15 
features such as dexterity. Does this mean that after all, PSF is related to motor impairment? The 16 
above investigation did not determine if those with slower movement speeds were capable of 17 
achieving higher speeds. It could be that in the task, one chose to move slower than their maximum 18 
speed. Those with slower movement speeds also reported heaviness of the affected limb [109], 19 
possibly a central sensory processing problem, which in turn may have led to choosing lower 20 
movement speeds. Those with  lower movement speeds also exhibited low motor cortex excitability 21 
[106]. It is unclear if the two findings have a direct relationship as it has previously been shown that 22 
motor cortex excitability does not encode movement speeds [110], however is crucial in motor 23 
learning involving movement speeds [111]. Low motor cortex excitability was also significantly 24 
correlated with high levels of PSF, but interestingly, voluntary activation, a measure of excitability of 25 
structures upstream of motor cortex such as secondary motor areas, was not significantly related to 26 
fatigue. Thus, PSF appears to be associated with behavioural [108] and perceptual [109] sensorimotor 27 
deficits  with some underlying neurophysiological [106] perturbations in the sensorimotor pathway.  28 
 29 
Do any of the above findings suggest a causal role for motor and cognitive, behavioural and 30 
neurophysiological deficits, in development of PSF? The attention and executive impairments seen in 31 
PSF are global. Structural and physiological changes remote to the site of lesion resulting in global 32 
attentional and executive impairment is a well-documented phenomenon after stroke. However, 33 
without further investigations the above correlations between fatigue and attention/executive 34 
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impairment cannot be interpreted as being causal to fatigue., fatigue related sensorimotor 1 
behavioural, physiological and perceptual findings are confined to the affected hemisphere. Should 2 
they be a consequence of fatigue, one would expect a more global effect on behaviour, hence there 3 
may be a causal role for sensorimotor alterations in development of fatigue. A small pilot 4 
interventional study reported significant benefits to using cognitive behavioural therapy and graded 5 
exercise [112] for PSF. However, the effect size was not great enough to suggest that the intervention 6 
had targeted the underlying causal neural perturbations, but rather may have succeeded in 7 
compensating for some of the fatigue resultant behavioural changes. Moreover, the length of follow-8 
up was not sufficient to determine fully the long-term effects of the intervention.   9 
 10 
Active Inference based theoretical model of post-stroke fatigue [20,113–115] 11 
 12 
Poor attention, slower processing speed, diminished memory, reduced movement speed and 13 
perceived limb heaviness: how might the above deficits give rise to fatigue, when no seemingly direct 14 
cause for fatigue such as sustained exertion exist? To answer this, we must first understand how 15 
sustained exertion might give rise to fatigue. With sustained activity, performance in the task drops 16 
and importantly, subjects report fatigue, or more precisely, the need for higher effort to maintain task 17 
performance and at task failure, the inability to exert required effort to perform the task [116]. It is 18 
also well established that task performance and report of fatigue are not correlated [117]. Hence, the 19 
notion of higher effort is inextricably linked to fatigue whilst drop in task performance itself may be 20 
seen as behavioural consequence of fatigue. A dissociation between task performance and fatigue, 21 
with a closer link between effort or ‘estimated action cost’ and fatigue, is indicative of a possible causal 22 
link between estimated action cost and fatigue. A recent review discussed how the low motor cortex 23 
excitability, reduced movement speed and perceived limb heaviness could underpin aberrant 24 
‘estimated action cost’ or effort. Aberrant effort results in higher than normally required effort for 25 
everyday tasks [20]. Persistent high effort for simple tasks gives rise to fatigue. This fits well with the 26 
clinical symptoms of PSF, such as, fatigue without prior activity, fatigue that does not respond to rest 27 
and fatigue that limits everyday activities.  28 
 29 
Effort is a perceptual inference that has its origins in intention (efferent information) and is modulated 30 
by feedback (afferent information). The active inference theory of sensorimotor control integrates 31 
efferent and afferent inputs to explain movement initiation and motor control [113] and provides a 32 
framework within which effort, as defined above may arise [118]. The active inference theory of 33 
sensorimotor control postulates that the (efferent) output from cortico-motor system is in the form 34 
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of sensory (proprioceptive) predictions and (afferent) input from the somatosensory systems is in the 1 
form of sensory (prediction) errors. For a movement to be initiated, i.e. sensory predictions to be 2 
fulfilled, ascending sensory errors must not be attended to and to maintain status quo, sensory errors 3 
must be attended to. This property of altering precision of sensory errors is known as ‘sensory 4 
attenuation’. It has been postulated [118] that in post-stroke fatigue, inference of high effort could be 5 
the result of poor sensory attenuation. In the context of muscle contractions, the inability to suppress 6 
ascending prediction errors is inferred by the brain as needing more than the estimated effort, to 7 
perform the contraction. The motor cortex encodes prediction errors as shown by a suppression of 8 
sensory attenuation when motor cortex excitability is artificially reduced using non-invasive brain 9 
stimulation [119]. The observed reduction in motor cortex excitability in stroke survivors with high 10 
fatigue [106] further suggests poor sensory attenuation may be the mechanism by which fatigue 11 
arises. Evidence from other pathological conditions implicating dopaminergic systems in poor sensory 12 
attenuation [115] combined with post-stroke fatigue related molecular disturbances and pre-clinical 13 
work in muscle metabolism post-stroke [120,121] lend support to both central and peripheral 14 
mechanisms playing a role in poor sensory attenuation.  15 
 16 
Conclusion  17 
 18 
Post-stroke fatigue is highly prevalent and has a significant impact on lives of stroke survivors. Here 19 
we summarise our current knowledge about possible causes of post-stroke fatigue. Preliminary 20 
evidence supports the idea of stroke triggered early biochemical imbalance resulting in altered 21 
homeostasis, leading to beliefs about estimated action cost that manifest as behavioural changes 22 
which fail to reverse in the long term presenting as chronic post-stroke fatigue. Understanding 23 
mechanisms of post-stroke fatigue is a relatively new field of study and several outstanding questions 24 
need to be addressed by future investigations.  25 
Early changes in the biochemical environment after stroke has been implicated in development of a 26 
whole host of affective symptoms including fatigue, some of which have been discussed here. It is as 27 
yet unclear if there are biochemical imbalances in the chronic phase that might account for fatigue. 28 
Further work is also required to identify what biochemical signatures distinguish fatigue from 29 
depression. A limitation of current investigations is that all studies rely on biochemical markers in the 30 
plasma, which is not necessarily a reflection of the biochemical environment in the brain. 31 
Cerebrospinal fluid markers of fatigue will help establish more accurately fatigue specific triggers.  32 
The main behavioural consequence of fatigue is a significant reduction in self-initiated voluntary 33 
behaviour, possibly driven by altered effort calibration as discussed previously. Identifying specific 34 
 13 
 
motor and non-motor behaviours that are affected by effort mis-calibration might be helpful in 1 
developing interventions for managing fatigue. However, it is imperative that we first establish that 2 
the identified behavioural alterations are mediators of fatigue and not merely a result of fatigue. 3 
Future work must also concentrate on developing and validating frameworks within which one can 4 
explain fatigue, such as the one proposed here, the active inference based framework of fatigue.  5 
In summary, fatigue is a complicated phenomenon with several contributing factors, most of which 6 
are poorly understood. Here, we have attempted to bring together several lines of enquiry and 7 
proposed a potential unified framework of fatigue.  8 
 9 
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